# Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus

> **NCT02441543** · — · COMPLETED · sponsor: **Istituto Clinico Humanitas** · enrollment: 45 (actual)

## Conditions studied

- SOLID TUMOR

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02441543
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2018-04
- **Final completion:** 2018-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02441543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02441543, "Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02441543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*